Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study links gene mutation to miscarriage risk:

This article was originally published in Clinica

Executive Summary

A genetic mutation that predisposes women to developing blood clots, has been linked with an increased risk of miscarrying during pregnancy at around 12 weeks, says a team at St Mary's Hospital NHS Trust, In London. Results from a trial show that just 40% of women with a history of recurrent miscarriage and mutation on their Factor V gene, known as Factor V Leiden, had live births, compared with 70% of women with a similar history but with a normal Factor V gene. The findings appear in Human Reproduction (January 30).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel